Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Pulm Pharmacol Ther ; 21(3): 449-54, 2008.
Article in English | MEDLINE | ID: mdl-17869148

ABSTRACT

The vascular bed in nasal mucosa of different species, including human, is highly vascularized and an extensive sinusoidal network of large capacitance vessels is present deep within the submucosa. When this network of venous sinusoids is engorged with blood, the swollen mucosa reduces the size of the airway lumen and congestion ensues. Nasal vasculature tone is strongly influenced by the sympathetic nervous system and the only drugs approved specifically to relieve vascular nasal obstruction are alpha-adrenoceptor sympathomimetic agents. Due to their vasoconstrictor action, the sympathomimetic decongestants oppose vasodilation, reducing nasal airway resistance and thus facilitating nose breathing. However, standard decongestants that are non-selective alpha-adrenoceptor agonists are associated with the potential for side-effect liabilities including hypertension, stroke, insomnia and nervousness. We propose than a selective alpha 2-adrenoceptor agonist, by acting preferentially on nasal venous capacitance vessels, will elicit decongestion with a reduced side-effect liability. In the present study, we evaluated the effects of the selective alpha 2-adrenoceptor agonist BHT-920 in a real-time tissue contractility assay using isolated pig nasal explants and in an in vivo cat model of congestion. The vasoconstrictor and decongestant effects of BHT-920 were compared to the non-selective alpha-adrenoceptor agonist epinephrine and the standard decongestant oxymetazoline. Our results showed that the alpha 2-adrenoceptor agonist BHT-920 preferentially contracts venous sinusoids confirming previous observations [Corboz MR, Varty LM, Rivelli MA, Mutter JC, Mingo G, McLeod R, et al. Effects of an alpha 2-adrenoceptor agonist in nasal mucosa. Arch Physiol Biochem 2003;11: 335-6, Corboz MR, Rivelli MA, Varty LM, Mutter J, Cartwright M, Rizzo CA, et al. Pharmacological characterization of postjunctional alpha-adrenoceptor in human nasal mucosa. Am J Rhinol 2005;19: 495-502] and displays decongestion without affecting blood pressure. Therefore, an alpha 2-adrenoceptor agonist, by causing constriction in the capacitance vessels of nasal mucosa, can produce nasal decongestion without the effects on blood pressure observed with the standard selective alpha 1-adrenoceptor and non-selective alpha-adrenoceptor sympathomimetic decongestants.


Subject(s)
Adrenergic alpha-2 Receptor Agonists , Adrenergic alpha-Agonists/pharmacology , Nasal Decongestants , Administration, Topical , Animals , Azepines/pharmacology , Blood Pressure/drug effects , Cats , Dose-Response Relationship, Drug , Epinephrine/pharmacology , Female , Male , Muscle Contraction/physiology , Nasal Mucosa/innervation , Nasal Mucosa/physiology , Oxymetazoline/pharmacology , Receptors, Adrenergic, alpha-2 , Swine , p-Methoxy-N-methylphenethylamine/pharmacology
2.
Pulm Pharmacol Ther ; 20(2): 149-56, 2007.
Article in English | MEDLINE | ID: mdl-16809058

ABSTRACT

Nasal congestion, one of the major disease features of rhinitis, is induced by the filling of venous sinusoids causing mucosal engorgement with resultant obstruction of nasal airflow. The only available drugs that directly target the underlying vascular features driving nasal obstruction are the sympathomimetic alpha-adrenoceptor agonists due to their vasoconstrictor action. However, standard decongestants are nonselective alpha-adrenoceptor agonists, which have the potential for side-effects liabilities such as hypertension, stroke, insomnia and nervousness. In the present study, the effects of nonsubtype selective alpha(2)-adrenoceptor agonists BHT-920 and PGE-6201204 were evaluated in several isolated nasal mucosa contractile bioassays including dog, pig and monkey, and in a real-time tissue contractility assay using isolated pig nasal explants for BHT-920. The decongestant activity of PGE-6201204 was evaluated in vivo in a cat model of experimental congestion. Our results showed that alpha(2)-adrenoceptor agonists (1) contract nasal mucosa of different species, (2) exert a preferential vasoconstrictor effect on the capacitance vessels (veins and sinusoids), and (3) elicit decongestion. In conclusion, a selective alpha(2)-adrenoceptor agonist causing constriction preferentially in the large venous sinusoids and veins of nasal mucosa and producing nasal decongestion is expected to show efficacy in the treatment of nasal congestion without the characteristic arterio-constrictor action of the standard nonselective sympathomimetic decongestants.


Subject(s)
Adrenergic alpha-2 Receptor Agonists , Adrenergic alpha-Agonists/pharmacology , Nasal Decongestants/pharmacology , Nasal Mucosa/drug effects , Adrenergic alpha-2 Receptor Antagonists , Adrenergic alpha-Agonists/administration & dosage , Adrenergic alpha-Antagonists/pharmacology , Animals , Azepines/pharmacology , Cats , Dogs , Dose-Response Relationship, Drug , Epinephrine/pharmacology , Female , In Vitro Techniques , Macaca fascicularis , Macaca mulatta , Male , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Nasal Decongestants/administration & dosage , Nasal Mucosa/blood supply , Nasal Mucosa/physiology , Prazosin/pharmacology , Swine , Swine, Miniature , Vasoconstriction/drug effects , Yohimbine/pharmacology , p-Methoxy-N-methylphenethylamine/pharmacology
4.
Auton Autacoid Pharmacol ; 23(4): 208-19, 2003 Aug.
Article in English | MEDLINE | ID: mdl-15084187

ABSTRACT

1. Pig nasal mucosal strips were incubated with alpha-adrenoceptor antagonists followed by alpha2-adrenoceptor agonist concentration-response curves. 2. Contractions elicited by the alpha2-adrenoceptor agonists BHT-920 (pD2 = 6.16 +/- 0.07), UK 14,304 (pD2 = 6.89 +/- 0.13) and PGE-6201204 (pD2 = 7.12 +/- 0.21) were blocked by the alpha2-adrenoceptor antagonist yohimbine (0.1 microm). In contrast, the alpha1-adrenoceptor antagonist prazosin (0.03 microm) had no effect on the BHT-920-, UK 14,304- and PGE-6201204-induced contractions, but blocked the contractile response to the alpha(1)-adrenoceptor agonist phenylephrine (pD2 = 5.38 +/- 0.04) and the mixed alpha1- and alpha2-adrenoceptor agonist oxymetazoline (pD(2) = 6.30 +/- 0.22). 3. The alpha2-adrenoceptor antagonist yohimbine (0.01-0.1 microm, pA2 = 8.04), alpha2B/C-adrenoceptor antagonist ARC 239 (10 microm, pK(b) = 6.33 +/- 0.21), alpha2A/C-adrenoceptor antagonist WB 4101 (0.3 microm, pK(b) = 8.01 +/- 0.24), alpha2A-adrenoceptor antagonists BRL44408 (0.1 microm, pK(b) = 6.82 +/- 0.34) and RX 821002 (0.1 microm, pKb = 8.31 +/- 0.35), alpha2C-adrenoceptor antagonists spiroxatrine (1 microm, pKb = 7.32 +/- 0.32), rauwolscine (0.1 microm, pKb = 8.16 +/- 0.14) and HV 723 (0.3 microm, pKb = 7.68 +/- 0.14) inhibited BHT-920-induced contractions in pig nasal mucosa. 4. The present antagonist potencies showed correlations with binding affinity estimates (pKi) obtained for these antagonists at the human recombinant alpha2A- and alpha2C-adrenoceptors (r = 0.78 and 0.83, respectively) and with binding affinity estimates (pKd) obtained in pig native alpha2A- and alpha2C-monoreceptor assays (r = 0.85 and 0.78, respectively). No correlation was observed for the alpha2B-subtype. 5. In conclusion, contractile responses to phenylephrine, BHT-920, UK 14,304, PGE-6201204 and oxymetazoline indicate that alpha1- and alpha2-adrenoceptors are present and mediate vasoconstriction in pig nasal mucosa. Furthermore, correlation analysis comparing antagonist potency in pig nasal mucosa with affinities for human recombinant alpha2-adrenoceptors and native pig alpha2-adrenoceptors suggest that alpha2A- and alpha2C-adrenoceptor subtypes constrict pig nasal mucosa vasculature.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists , Adrenergic alpha-Antagonists/metabolism , Nasal Mucosa/metabolism , Receptors, Adrenergic, alpha-2/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , CHO Cells , Cricetinae , Dose-Response Relationship, Drug , Female , Humans , In Vitro Techniques , Male , Nasal Mucosa/drug effects , Protein Binding/drug effects , Protein Binding/physiology , Swine
5.
Eur J Pharmacol ; 402(1-2): 171-9, 2000 Aug 18.
Article in English | MEDLINE | ID: mdl-10940371

ABSTRACT

The isolated perfused guinea pig lung was used to investigate the effect of nociceptin against bronchoconstriction elicited by endogenous and exogenous tachykinins. The opioid receptor-like 1 (ORL1) receptor agonist, nociceptin/orphanin FQ (0.001-1 microM) produced a dose-related inhibition of the capsaicin-induced bronchoconstriction (10(-5)-10(3) microg) in isolated guinea pig lung (P<0.05), a response mediated by the release of endogenous tachykinins from lung sensory nerves. The new ORL1 receptor antagonist 1-[(3R, 4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397) (0.3 microM) significantly blocked the inhibitory effect of nociceptin/orphanin FQ (0.01 microM) on capsaicin-induced bronchoconstriction, whereas the non-selective opioid receptor antagonist naloxone (1 microM) had no effect. Nociceptin/orphanin FQ (1 microM) did not affect the bronchoconstriction induced exogenously by the tachykinin NK2 receptor agonist neurokinin A. In conclusion, the present data provide evidence that nociceptin inhibits capsaicin-evoked tachykinin release from sensory nerve terminals in guinea pig lung by a prejunctional mechanism. This inhibitory action occurs independently from activation of opioid receptors. The present study also indicates that J-113397 is a potent ORL1 receptor antagonist.


Subject(s)
Bronchoconstriction/drug effects , Capsaicin/antagonists & inhibitors , Lung/drug effects , Narcotic Antagonists , Opioid Peptides/pharmacology , Receptors, Opioid/agonists , Animals , Benzimidazoles/pharmacology , CHO Cells , Capsaicin/pharmacology , Cricetinae , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Guinea Pigs , In Vitro Techniques , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Piperidines/pharmacology , Sulfur Radioisotopes , Nociceptin Receptor , Nociceptin
6.
Eur J Pharmacol ; 366(1): 73-8, 1999 Jan 29.
Article in English | MEDLINE | ID: mdl-10064154

ABSTRACT

Studies were performed to assess the functional activity of histamine H3 receptors on neurogenic sympathetic end organ responses in cryopreserved human saphenous vein. (R)-alpha-methylhistamine inhibited electrical field stimulation-evoked contractile responses in a dose dependent manner (pD2 = 8.20). Prazosin (1 microM) and tetrodotoxin (1 microM) blocked the electrical field stimulation-evoked contractile responses in human saphenous vein indicating a sympathetic neural origin of these contractions. The histamine H3 antagonists thioperamide (pA2 = 8.41) and clobenpropit (pA2 = 10.10) produced parallel rightward shifts in the concentration response curve to (R)-alpha-methylhistamine in human saphenous vein and guinea pig ileum (pA2 = 8.59 and 9.83, respectively). Pretreatment with (R)-alpha-methylhistamine (1 microM) did not alter contractions to exogenous norepinephrine in human saphenous vein. In addition, clonidine (pD2 = 10.28) inhibited electrical field stimulation-evoked contractile responses in human saphenous vein which were blocked by yohimbine (30 nM, pA2 = 9.92) but did not alter the (R)-alpha-methylhistamine dose response curve. These results demonstrate the presence of functional presynaptic histamine H3 heteroreceptors on cryopreserved human saphenous vein sympathetic nerves that, upon activation, attenuate electrical field stimulation-evoked contractile responses in this vessel.


Subject(s)
Ileum/drug effects , Receptors, Histamine H3/drug effects , Saphenous Vein/drug effects , Adrenergic alpha-Antagonists/pharmacology , Aged , Animals , Dose-Response Relationship, Drug , Electric Stimulation , Female , Guinea Pigs , Histamine Agonists/pharmacology , Histamine Antagonists/pharmacology , Humans , Ileum/physiology , Imidazoles/pharmacology , In Vitro Techniques , Male , Methylhistamines/pharmacology , Middle Aged , Muscle Contraction/drug effects , Piperidines/pharmacology , Prazosin/pharmacology , Receptors, Histamine H3/metabolism , Saphenous Vein/physiology , Tetrodotoxin/pharmacology , Thiourea/analogs & derivatives , Thiourea/pharmacology , Yohimbine/pharmacology
7.
Eur J Pharmacol ; 350(1): R1-3, 1998 May 29.
Article in English | MEDLINE | ID: mdl-9683025

ABSTRACT

Tachykinin NK1 receptors are present on human pulmonary arteries. Addition of the specific tachykinin NK1 receptor agonist, [Met-OMe11]substance P produced a concentration-dependent relaxation (0.1 nM to 100 nM) in pulmonary arteries preconstricted with phenylephrine (30 microM). The EC50 (agonist concentration needed to produce 50% of the maximal relaxation) value for [Met-OMe11]substance P was 3.7+/-0.7 nM. The relaxation induced by [Met-OMe11]substance P was selectively inhibited by the tachykinin NK1 receptor antagonist CP 99994 (1 nM), with a pKb of 9.9+/-0.3. Treatment with the tachykinin NK2 receptor antagonist SR 48968 (100 nM) did not significantly affect the vasorelaxation due to [Met-OMe11]substance P (P > 0.05, one-way analysis of variance; ANOVA).


Subject(s)
Pulmonary Artery/physiology , Receptors, Neurokinin-1/physiology , Vasodilation , Dose-Response Relationship, Drug , Humans , Phenylephrine/pharmacology , Piperidines/pharmacology , Pulmonary Artery/drug effects , Pulmonary Artery/metabolism , Receptors, Neurokinin-1/drug effects , Substance P/pharmacology , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects
8.
Bioorg Med Chem Lett ; 8(16): 2157-62, 1998 Aug 18.
Article in English | MEDLINE | ID: mdl-9873505

ABSTRACT

Sulfonamides derived from 4(5)-(omega-aminoalkyl)-1H-imidazoles containing chain lengths of three- to five-carbons were synthesized. Good to moderate H3 receptor binding affinities were observed for several butyl and pentyl homologs, whereas binding affinities were considerably weaker in the propyl series. Separation of the imidazole ring and the sulfonamide unit by a four- or five-carbon tether afforded potent H3 receptor antagonists.


Subject(s)
Histamine Antagonists/chemical synthesis , Histamine/analogs & derivatives , Piperidines/chemical synthesis , Receptors, Histamine H3/physiology , Sulfonamides/chemical synthesis , Animals , Brain/metabolism , Cell Membrane/metabolism , Drug Design , Guinea Pigs , Histamine/chemical synthesis , Histamine/chemistry , Histamine/pharmacology , Histamine Antagonists/chemistry , Histamine Antagonists/pharmacology , Kinetics , Molecular Structure , Piperidines/chemistry , Piperidines/pharmacology , Receptors, Histamine H3/drug effects , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...